Lancet
Beyond's analysis on Lancet
- — PeproMene Bio achieves breakthrough clinical milestone with Lancet publication for B-cell lymphoma CAR T-cell therapy
- — PeproMene Bio's PMB-CT01 demonstrates deep remission in B-cell lymphomas even after CD19 CAR-T failure
- — PeproMene Bio reports breakthrough Phase 1 results for BAFF-R targeted CAR T-cell therapy in The Lancet
Recent news mentioning Lancet
- — Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
- — Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
- — PeproMene Bio gibt die Veröffentlichung bahnbrechender Ergebnisse einer klinischen Phase-1-Studie in The Lancet bekannt, die tiefe und anhaltende vollständige Remissionen bei rezidivierten/refraktären B-Zell-Lymphomen belegen, auch nach vorherigem Versagen einer CD19-CAR-T-Zell-Therapie
- — PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
- — PeproMene Bio annonce la publication dans The Lancet des résultats d'un essai clinique de phase 1 démontrant des réponses complètes profondes et durables dans les lymphomes à cellules B récidivants ou réfractaires, y compris après l'échec d'un traitement par cellules CAR-T ciblant le CD19
- — PeproMene Bio anuncia la publicación en The Lancet de los resultados de su ensayo clínico de fase 1
- — InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
- — Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis